Cidara Therapeutics, Inc. (CDTX)

Cidara Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-182.98	-169.83	-22.93	-33.58	-42.47	-72.11
Depreciation & Amortization	0.23	0.23	0.12	0.14	0.19	1.05
Other Amortization	0.17	0.18	0.08	-	0	0.01
Stock-Based Compensation	4.85	3.91	3.06	3.53	4.01	4.09
Other Operating Activities	-4.14	1.1	1.16	0.98	-1.41	0.02
Change in Accounts Receivable	5.31	14.28	-10.41	-0.48	5.82	-11.17
Change in Inventory	7.27	6.1	-6.1	-	-	-
Change in Accounts Payable	11.63	-1	8.89	-2.37	-1.09	6.59
Change in Unearned Revenue	-26.21	-29.34	-5.8	2.65	7.32	15.21
Change in Income Taxes	5.62	8.01	6.51	3.95	-	-
Change in Other Net Operating Assets	-15.33	-11.97	3	-3.29	2.39	1.91
Operating Cash Flow	-191.84	-176.53	-22.43	-28.47	-25.23	-54.41
Capital Expenditures	-0.11	-0.13	-0.51	-0.12	-0.04	-0.19
Investing Cash Flow	0.08	-0.13	-0.51	-0.12	-0.04	-0.19
Long-Term Debt Repaid	-	-0.28	-	-2.59	-4.44	-2.96
Net Debt Issued (Repaid)	-0.28	-0.28	-	-2.59	-4.44	-2.96
Issuance of Common Stock	337.5	337.38	25.98	2.36	49.04	40.24
Repurchase of Common Stock	-	-0.04	-	-	-	-
Other Financing Activities	0	-	-	-0.72	-	-
Financing Cash Flow	337.23	337.06	25.98	-0.95	44.6	37.28
Net Cash Flow	145.47	160.4	3.05	-29.54	19.32	-17.32
Free Cash Flow	-191.95	-176.66	-22.94	-28.59	-25.27	-54.6
Free Cash Flow Margin	-63557.95%	-13855.84%	-98.51%	-121.69%	-50.98%	-452.45%
Free Cash Flow Per Share	-21.91	-27.82	-5.25	-8.19	-9.64	-26.27
Cash Interest Paid	-	-	-	0.04	0.23	0.45
Cash Income Tax Paid	0.1	0.1	0.8	-	-	-
Levered Free Cash Flow	-82.97	-67.09	-1.7	-1.34	-13.44	-34.66
Unlevered Free Cash Flow	-82.97	-67.09	-1.7	-1.34	-13.31	-34.5
Change in Net Working Capital	19.47	14.04	-13.22	-9.57	-8.94	-5.45

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q